Alkermes (ALKS) is a poster child for the difficulties of investing in early stage biotech. It has been successful over the years in getting FDA approvals and big pharma licensing agreements for a variety of significant therapies, however it has never been a successful investment vehicle.
This article reviews its prospects going forward.
Alkermes has been a boom/bust recidivist and an overall laggard
Alkermes has been around. It IPO'd in 1991 on the leading edge of a class of class biotechs that IPO'd between 1991-94 including: Gilead (GILD) [market cap $84.45